Astellas Pharma Aktie

11,40 EUR -0,20 EUR -1,72 %

15:17:45

STU

2.124,00 JPY -10,00 JPY -0,47 %

08:30:00

TOKIO

Astellas Pharma jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Marktkap.21,61 Mrd. EUR

KGV15,48Div. Rendite3,10%

WKN856273

ISINJP3942400007

SymbolALPMF

Astellas Pharma Aktien News

Sortieren:Datum Meistgelesen

16.11.23PR NewswireAstellas to Acquire Propella Therapeutics

16.11.23PR NewswireAstellas Announces Data from ASPIRO Study in X-linked Myotubular Myopathy Published in The Lancet Neurology

04.11.23PR NewswireIZERVAY™ (avacincaptad pegol intravitreal solution) Monthly or Every Other Month Reduced Geographic Atrophy Lesion Growth Through 2 Years

22.10.23PR NewswireGroundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-L...

16.10.23PR NewswireAstellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023

13.10.23PR NewswireAstellas Receives Positive CHMP Opinion for VEOZA™ (fezolinetant)

11.10.23PR NewswireAstellas, BioLabs and Mitsui Fudosan Announce a Collaboration to Enhance the Life Science Ecosystems in Tsukuba and Kashiwa-no-ha, Japan

22.09.23PR NewswirePADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer i...

20.09.23PR NewswireTwo-time Emmy® Award-Winning Actor, Eric Stonestreet, Partners with Iveric Bio to Raise Awareness of Geographic Atrophy (GA)

19.09.23PR NewswireIveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

19.09.23PR NewswireAstellas Venture Management and MBC BioLabs Announce the 5th Annual Astellas Future Innovator Prize

18.09.23PR NewswireAstellas Highlights VEOZAH™ (fezolinetant) Data at the 2023 Annual Meeting of The Menopause Society

14.09.23PR NewswireAstellas to Invest more than €330 Million in a New State-of-the-Art Facility in Tralee, Co. Kerry. Ireland

13.09.23PR NewswireEuropean Medicines Agency Validates Type II Variation for Astellas' XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

23.08.23PR NewswireFDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

18.08.23PR NewswireEuropean Medicines Agency Accepts Iveric Bio's Marketing Authorization Application for Avacincaptad Pegol for Geographic Atrophy

10.08.23PR NewswireAstellas to Open New Life Sciences Facility in DivcoWest's Cambridge Crossing Neighborhood

07.08.23PR NewswireAstellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy

05.08.23PR NewswireIveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy

01.08.23PR NewswireChina's National Medical Products Administration Accepts Astellas' Biologics License Application for Zolbetuximab

18.07.23PR NewswireAstellas and Eko Health Announce Agreement to Incorporate Next Generation Eko CORE 500™ Digital Stethoscope into Z1608, an Innovative Solution Under Development for Heart Failure Patients Built on...

14.07.23PR NewswireEuropean Medicines Agency Accepts Astellas' Marketing Authorization Application for Zolbetuximab

12.07.23PR NewswireAstellas Completes Acquisition of Iveric Bio

11.07.23PR NewswireAstellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets

06.07.23PR NewswireAstellas Announces U.S. FDA Grants Priority Review for Zolbetuximab Biologics License Application

29.06.23PR NewswireAstellas Establishes Open Innovation Hub for Tumor Microenvironment Research with Cutting-Edge Spatial Biology, in Mitsui Fudosan's "MITSUI LINK-Lab KASHIWA-NO-HA 1"

15.06.23PR NewswireAstellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders

09.06.23PR NewswireGilteritinib as Maintenance Therapy Demonstrated Benefit in Subgroups of FLT3-ITD Acute Myeloid Leukemia Patients

09.06.23PR NewswireAstellas Submits New Drug Application for Zolbetuximab in Japan

08.06.23PR NewswireAstellas and Kate Therapeutics Announce Exclusive License Agreement for KT430

Astellas Pharma News

Astellas Pharma News: auf dieser Seite finden Sie alle Astellas Pharma News und Nachrichten zur Astellas Pharma Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Astellas Pharma News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Astellas Pharma News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.